VytronUS, Inc., a Sunnyvale, Calif.-based medical device company developing novel technologies for the treatment of cardiac arrhythmias, secured $49m in Series C equity financing.
Backers included Apple Tree Partners, NEA, BioStar Ventures, and Windham Venture Partners.
The company intends to use the funds for technology refinements and clinical trials of its proprietary Low-Intensity Collimated Ultrasound (LICU™) Cardiac Mapping & Ablation System to treat atrial fibrillation and other arrhythmias.
Led by John Pavlidis, CEO, VytronUS is developing an integrated imaging and ablation platform for cardiac electrophysiologists. Harnessing the capability of ultrasound energy, the company’s system creates a high resolution image of the interior of the heart for procedure planning and allows the physician to draw a desired treatment pattern on the image at the workstation.